Upregulation of CD19 by low‐dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma by Ying Ni, Qun Zhang, Xiaochen Tang, Xiuchun Li, Shiguang Ye, Yan Lu, Aibin Liang, Ping Li

“…In recent years, CD19 Chimeric antigen receptor T (CAR T) cell immunotherapy has significantly improved the cure rate of B-NHL patients, but there are still some patients who cannot achieve remission after treatment, or relapse after remission. …”
Get full text

Targeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion by Yang Xia, Chunye Huang, Min Zhong, Hongguang Zhong, Ruiwen Ruan, Jianping Xiong, Yangyang Yao, Jing Zhou, Jun Deng

“…The review thoroughly examines both clinical and practical evidence regarding the use of c-MET inhibitors alongside PD-1/PD-L1 inhibitors, emphasizing that focusing on c-MET with immunotherapy enhances the effectiveness of treating MET tumors exhibiting elevated PD-L1 expression.…”
Get full text

RETRACTED ARTICLE: Clinical and immuno-proteomic approach on Lantana camara pollen allergy—a major health hazard by Kavita Ghosal, Bodhisattwa Saha, Swati Gupta Bhattacharya

“…The allergens identified thereof can be used to prepare hypoallergenic vaccine candidates and design immunotherapy trials against LC pollen and other aeroallergen carriers which are cross-reactive and harbor similar proteins.…”
Get full text

Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC by Masayuki Shirasawa, Tatsuya Yoshida, Takaji Matsutani, Yuki Takeyasu, Naoko Goto, Shigehiro Yagishita, Shigehisa Kitano, Hiroaki Kuroda, Toyoaki Hida, Takayasu Kurata, Yuichiro Ohe

Get full text

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer by Qichen Zhang, Xiaojuan Han, Jiayi Liu, Hui Qiao

“…Adverse effects were comparable between the groups in terms of thyroid function (p = 0.898), but bone marrow suppression and gastrointestinal reactions were significantly less severe in the PD‐L1 group (p = 0.047 and p = 0.002). Conclusion Immunotherapy combined with chemotherapy offers significant benefits for advanced SCLC patients, irrespective of the type of inhibitor used. …”
Get full text

Hijacking of the nervous system in cancer: mechanism and therapeutic targets by Yu Zhang, Qili Liao, Xuyang Wen, Jiayan Fan, Tifei Yuan, Xuemei Tong, Renbing Jia, Peiwei Chai, Xianqun Fan

“…Importantly, neural activity is also implicated in modulating the efficacy of therapeutic interventions, including immunotherapy. On the contrary, the nervous system potentially has a suppressive effect on tumorigenesis, further underscoring a dual-edged role of neurons in cancer progression. …”
Get full text

The magnitude of exercise‐induced progenitor cell mobilisation and extravasation is positively associated with cardiorespiratory fitness by Mark Ross, Sarah Aldred, Mark T. Drayson, Jos A. Bosch, James E. Turner

Get full text

Case report: A case of type 1 diabetes with diabetic ketoacidosis induced by envafolimab treatment in hepatocellular carcinoma by Youjia Li, Kai Qu, Xiuli Li, Xin Yang, Kanghuai Zhang, Jiao Xie

“…Recognizing the limitations of current understanding, there is a clear call for further research, particularly on identifying biomarkers that may predict adverse reactions to immunotherapy, to guide precision medicine and improve patient safety.…”
Get full text

Expression Levels of IL-17A, IL-17F, IL-17RA, and IL-17RC in Prostate Cancer with Taking into Account the Histological Grade according to Gleason Scale in Comparison to Benign Pros... by Marlena Janiczek, Łukasz Szylberg, Paulina Antosik, Anna Kasperska, Andrzej Marszałek

“…A study on IL-17 may become a starting point for further research on an attempt to use, for example, immunotherapy in PCa.…”
Get full text

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors by Ichiro Yamauchi, Daisuke Yabe

“…Given the increasing diversity and complexity of cancer immunotherapy, it is essential to vigilantly screen for thyroid irAEs.…”
Get full text

Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients by Zhaoyue Yan, Yushuai Gao, Jinliang Yu, Zhiyuan Shen, Xingyao Bu

“…Moreover, the high-risk group had a greater immune infiltration and was most likely to benefit from immunotherapy. Gene set enrichment analysis suggested that immune and oncogenic pathways were enriched in high-risk glioma patients. …”
Get full text

Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma by Zhuning Wang, Junqiao Yao, Tengyu Dong, Xing Niu

“…High-risk subset displayed higher somatic mutations, CNVs, TMB, SNV neoantigens, aneuploidy score, CTA score, homologous recombination defects, and intratumor heterogeneity, cytolytic activity, CD8+ T effector, and antigen processing machinery, proving that this subset might benefit from immunotherapy. Increased stemness indexes and activity of oncogenic pathways might contribute to undesirable prognostic outcomes for high-risk subset. …”
Get full text

Identification of cuproptosis and ferroptosis-related subtypes and development of a prognostic signature in colon cancer. by Yinghao He, Fuqiang Liu, Qingshu Li, Zheng Jiang

“…In summary, our study provides a relatively accurate prognostic tool for colon cancer patients, offering guidance for treatment selection and indicating the potential of immunotherapy in colon cancer.…”
Get full text

Pan-Cancer Analysis of the Prognostic and Immunotherapeutic Value of PDGFB by Bai Y, Wang X, Wang B

“…We confirmed that PDGFB positively correlated with CD8 and PDL1 expression in lower grade glioma.Conclusion: This study concludes that PDGFB may serve as a potential prognostic marker and a potential targetable pathway in cancer immunotherapy. Overall, the study sheds new light on the role of PDGFB in cancer and highlights its potential clinical significance.Keywords: PDGFB, pan-cancer, prognosis, immune cell infiltration, biomarker…”
Get full text

Pan-cancer analysis of SOX2: Prognostic implications and potential as a therapeutic target in immune checkpoint modulation by Shoukai Yu, Lingmei Qian, Liling Xu, Jun Ma

“…These findings underscore SOX2's potential in regulating immune checkpoints and enhancing cancer immunotherapy.…”
Get full text

The Alteration and Clinical Significance of Th22/Th17/Th1 Cells in Patients with Chronic Myeloid Leukemia by Ping Chen, Min Wang, Daqi Li, Yan Jia, Na He, Wei Li, Daoxin Ma, Chunyan Ji

“…All these results demonstrated that Th22, Th17, and Th1 cells might be important therapeutic targets in CML and could facilitate a better outcome for tumor immunotherapy.…”
Get full text

Solitary metastasis in the internal auditory canal from non-small cell lung carcinoma: A case report by Julie De Boos, Marie Bruyneel, Ionela Bold

“…Case presentation: A 59-year-old active smoker was initially diagnosed with a locally advanced, unresectable stage IIIA Pancoast tumor (NSCLC, cT4N1M0) and treated with concurrent chemoradiation (cisplatin-pemetrexed) followed by immunotherapy (durvalumab). A subsequent PET CT scan indicated a complete metabolic response. …”
Get full text

Dual Role of Bacteria in Carcinoma: Stimulation and Inhibition by Suad A Al-Hilu, Wisam H Al-Shujairi

“…However, the traditional cancer treatments that include chemotherapy, radiotherapy, surgery, and immunotherapy increase the chances of survival, and there are many side effects of these therapies, including the high toxicity of tissues and normal cells, could not penetrate the tumor cells, and resistance of these therapies by tumor cells. …”
Get full text

mRNA vaccines as cancer therapies by Shaoxiong Huang, Haiying Que, Manni Wang, Xiawei Wei, Yanjie Yin

“…This review provides an in-depth analysis of messenger RNA (mRNA) vaccines as a therapeutic approach for cancer immunotherapy, focusing on their molecular biology, classification, mechanisms, and clinical studies. …”
Get full text

GPR55 in the tumor microenvironment of pancreatic cancer controls tumorigenesis by Dušica Ristić, Thomas Bärnthaler, Eva Gruden, Melanie Kienzl, Laura Danner, Karolina Herceg, Arailym Sarsembayeva, Julia Kargl, Rudolf Schicho

“…Notably, anti-PD-1 immunotherapy increased tumor burden in WT mice, while this effect was absent in the GPR55 KO mice. …”
Get full text